Eil Lilly received accelerated FDA approval Friday for a drug that treats advanced cancers carrying a certain genetic signature. It’s the latest targeted cancer therapy to pass the regulatory bar and the first that addresses tumors characterized by aberrations in one particular gene.

The gene in question, RET, produces a protein involved in cell signaling. Approval of the Lilly (NYSE: LLY) drug, selpercatinib (Retevmo), covers non-small cell lung cancer (NSCLC), thyroid cancer, and the rarer medullary thyroid cancer, which originates from different cells than other thyroid cancers. Those cancer cells treated by the Lilly drug must have a genetic alteration… Read more »

UNDERWRITERS AND PARTNERS